Interstitial pneumonitis during imatinib therapy.
Isshiki
Ikuko
I
Division of Hematology and Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, Japan.
Yamaguchi
Kazuhiro
K
Okamoto
Shinichiro
S
D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects*; D001549:Benzamides; D005260:Female; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy; D008168:Lung / Q000000981:diagnostic imaging*; D017563:Lung Diseases, Interstitial / Q000139:chemically induced* / Q000000981:diagnostic imaging; D010879:Piperazines / Q000009:adverse effects*; D011239:Prednisolone / Q000627:therapeutic use; D011743:Pyrimidines / Q000009:adverse effects*; D014057:Tomography, X-Ray Computed
D000970:Antineoplastic Agents; D001549:Benzamides; D005938:Glucocorticoids; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D011239:Prednisolone